Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Condition:   Other Cancer Intervention:   Drug: ruxolitinib Sponsors:   Massachusetts General Hospital;   Incyte Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials